RAPT rapt.com: Net earnings per share for the last 12 months

RAPT Therapeutics, Inc. (RAPT) specializes in developing advanced oral compounds to combat cancer and cellular inflammation. The market value dynamics of the asset with the 50.40 indicator reflect the company's current status. The business is currently focusing on its most promising molecules while adjusting its clinical trial plan. This approach leverages a robust R&D foundation aimed at developing breakthrough therapies.
RAPT (RAPT Therapeutics): analytical breakdowns and indicator data

Year-over-year EPS growth (TTM) measures the relative change in earnings per share over a rolling twelve-month period. This model neutralizes seasonality, allowing investors to isolate systemic profitability trends from random factors. By analyzing the historical annual dynamics of TTM EPS, one can evaluate the effectiveness of capital management. For RAPT Therapeutics, Inc. (RAPT), the absence of revenue and rising clinical trial costs turn this indicator into a marker for the resource burn rate.